These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 7996707)

  • 1. [Myasthenia gravis: pathogenesis and therapeutic approach on the basis of molecular structure and immunogenicity of acetylcholine receptor].
    Takamori M
    Nihon Rinsho; 1994 Nov; 52(11):3038-45. PubMed ID: 7996707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: an approach to antigenic synthetic peptides.
    Takamori M; Hamada T; Okumura S
    J Neurol Sci; 1992 Jun; 109(2):182-7. PubMed ID: 1634900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular biology and immunology of acetylcholine receptor in relation to myasthenia gravis].
    Takamori M; Komai K; Iwasa K; Yoshikawa H
    Nihon Rinsho; 1997 Dec; 55(12):3315-21. PubMed ID: 9436457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A joint undertaking by molecular biology and immunology in search for the pathogenesis of neuromuscular synaptic disorders].
    Takamori M
    Nihon Rinsho; 1997 Dec; 55(12):3106-13. PubMed ID: 9436419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biochemical approaches to neuromuscular junction disorders].
    Takamori M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1363-4. PubMed ID: 9128412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MHC class II presentation of human acetylcholine receptor in Myasthenia gravis: binding of synthetic gamma subunit sequences to DR molecules.
    Yuen MH; Macklin KD; Conti-Fine BM
    J Autoimmun; 1996 Feb; 9(1):67-77. PubMed ID: 8845056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
    Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
    J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conformational modification enhances myasthenogenicity in synthetic peptide of acetylcholine receptor alpha-subunit.
    Takamori M; Okumura S; Komai K; Satake R
    J Neurol Sci; 1990 Nov; 99(2-3):219-27. PubMed ID: 2086725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes.
    Brocke S; Brautbar C; Steinman L; Abramsky O; Rothbard J; Neumann D; Fuchs S; Mozes E
    J Clin Invest; 1988 Dec; 82(6):1894-900. PubMed ID: 2461962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor.
    Matsuo H; Batocchi AP; Hawke S; Nicolle M; Jacobson L; Vincent A; Newsom-Davis J; Willcox N
    J Immunol; 1995 Oct; 155(7):3683-92. PubMed ID: 7561069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
    Wauben MH; Hoedemaekers AC; Graus YM; Wagenaar JP; van Eden W; de Baets MH
    Eur J Immunol; 1996 Dec; 26(12):2866-75. PubMed ID: 8977279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.
    Takamori M; Maruta T
    Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes.
    Infante AJ; Thompson PA; Krolick KA; Wall KA
    J Immunol; 1991 May; 146(9):2977-82. PubMed ID: 1707927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human acetylcholine receptor presentation in myasthenia gravis. DR restriction of autoimmune T epitopes and binding of synthetic receptor sequences to DR molecules.
    Manfredi AA; Yuen MH; Moiola L; Protti MP; Conti-Tronconi BM
    J Immunol; 1994 Apr; 152(8):4165-74. PubMed ID: 7511671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune responses against acetylcholine receptor: T and B cell collaboration and manipulation by synthetic peptides.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1997; 17(5-6):481-95. PubMed ID: 9419435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of anti-acetylcholine receptor-alpha antibody in vitro by peripheral blood lymphocytes of patients with myasthenia gravis: role of immunoregulatory T cells and monocytes.
    Ofosu-Appiah W; Mokhtarian F; Shirazian D; Grob D
    J Lab Clin Med; 1994 Aug; 124(2):231-41. PubMed ID: 8051487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptor.
    Protti MP; Manfredi AA; Wu XD; Moiola L; Howard JF; Conti-Tronconi BM
    J Immunol; 1991 Apr; 146(7):2253-61. PubMed ID: 1706391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
    Tzartos SJ; Sophianos D; Efthimiadis A
    J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.